Bright Peak Therapeutics rakes in $107m Series B

Bright Peak Therapeutics, a developer of cytokine immunotherapies to treat cancer and autoimmune disease, has raised $107 million in Series B financing.

ByIris Dorbian

10 June 2021•1 min read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.

Deals Healthcare Briefs

Bright Peak Therapeutics rakes in $107m Series B

Alexandria Venture Investments

BlackRock

Invus

Qatar Investment Authority

RA Capital

Versant Ventures

Related articles